What is Enzyme (MLN)?

Quick Facts

  • Token name: MLN (Melon)
  • Blockchain: Ethereum (ERC-20)
  • Founded: 2017, formerly known as Melon Protocol
  • Category: Decentralized on-chain asset management
  • Token role: Utility token for platform fees and developer incentives
  • Governance: Community-driven via the Enzyme Council
  • Key product: Vault-as-a-Service and Financial Instruments protocols

Introduction

Enzyme is a decentralized asset management protocol built on Ethereum. It enables individuals, funds, and institutions to create, manage, and invest in on-chain investment vehicles — all without relying on traditional financial intermediaries.

The platform's native token, MLN, powers the entire ecosystem, covering usage fees, developer incentives, and treasury funding.

History & Background

Enzyme was originally launched in 2017 under the name Melon Protocol, co-founded by Mona El Isa and Reto Trinkler with the goal of simplifying and democratizing finance. The project rebranded to Enzyme to better reflect its broader ambitions beyond fund management.

A major milestone came in 2021 when Enzyme v2 was released — a completely re-architected version of the protocol built with modularity and extensibility at its core.

How Enzyme Works

Enzyme uses smart contracts to automate key aspects of asset management. Users can spin up customizable on-chain vaults, define investment strategies, and open them to depositors — all in a permissionless, transparent environment.

The protocol offers a Vault-as-a-Service model alongside a suite of Financial Instruments products. These tools allow asset managers to track performance, manage risk, and integrate with other DeFi protocols such as liquid staking platforms.

Tokenomics

MLN is the native utility token of the Enzyme protocol. It is used primarily to pay platform usage fees. Fees collected in MLN are either burned or deposited into the Enzyme treasury to fund ongoing development and grants.

This dual-path model creates a deflationary pressure on token supply while also sustaining the protocol's long-term growth through treasury allocation. MLN also incentivizes developers to build on top of the Enzyme infrastructure.

Circulating supply ? 2.90 million MLN
Reserved supply ? 68,101 MLN
FOUNDATION
0x28C6c06298d514Db089934071355E5743bf21d60
68,101 MLN
FOUNDATION
0xF977814e90dA44bFA03b6295A0616a897441aceC
0 MLN
Total supply ? 2.96 million MLN
Max supply ? -- MLN
Updated 2w ago

Ecosystem & Use Cases

Enzyme serves a growing range of use cases beyond traditional fund management. Asset managers can deploy automated strategies, integrate with DeFi primitives, and earn fees from depositors.

Notable integrations include liquid staking protocols, enabling managers to stake ETH and track real-time earnings directly within vaults. A grants program further incentivizes builders to expand Enzyme's ecosystem into emerging DeFi niches.

Team, Governance & Community

The protocol is stewarded by Avantgarde Finance, the core development team behind Enzyme. Day-to-day governance and protocol decisions are overseen by the Enzyme Council, a body composed of technical experts and stakeholders.

The community engages through forums, Discord, and governance votes, ensuring the protocol evolves in alignment with user needs.

Advantages

  • Permissionless access: Anyone can launch an on-chain vault without intermediaries.
  • Smart contract automation: Reduces manual overhead and operational risk in asset management.
  • Composability: Integrates natively with major DeFi protocols for expanded strategies.
  • Transparent operations: All vault activity is verifiable on-chain.

Risks & Challenges

  • Smart contract risk: Bugs or exploits in on-chain code could affect vault assets.
  • Regulatory uncertainty: Decentralized asset management may face evolving regulatory scrutiny.
  • Adoption hurdles: Competing with established TradFi and newer DeFi asset management solutions.
  • Token demand: MLN's value is closely tied to actual protocol usage levels.

Long-Term Vision

Enzyme positions itself as global infrastructure for tokenized finance. The team aims to expand beyond fund management into a broad financial operating system — serving institutions, DAOs, and individual managers who need robust, on-chain tools for sophisticated investment strategies.

Frequently Asked Questions

Enzyme is a decentralized protocol on Ethereum that allows users to create and manage on-chain investment vaults. It removes the need for traditional financial intermediaries by automating asset management through smart contracts.

MLN is the native utility token of Enzyme, used to pay platform usage fees. Collected fees are either burned or sent to the Enzyme treasury to fund development and grants.

Melon Protocol was the original name of Enzyme, launched in 2017. It was rebranded to Enzyme to better reflect the project's expanded vision beyond traditional fund management.

Enzyme was co-founded by Mona El Isa and Reto Trinkler. The core development is led by Avantgarde Finance, which continues to maintain and evolve the protocol.

Vault-as-a-Service lets users deploy customizable on-chain investment vaults with defined strategies and permissions. Depositors can invest in these vaults, and managers earn fees for their services.

Yes, MLN is an ERC-20 token operating on the Ethereum blockchain. Its smart contract address is publicly verifiable on-chain.

Enzyme integrates with a variety of DeFi protocols, including liquid staking platforms. These integrations allow vault managers to deploy more complex and diversified on-chain strategies.

Enzyme is governed by the Enzyme Council, a body made up of technical experts and community stakeholders. The community can also participate through governance votes and community forums.